Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ensysce Biosciences (ENSC) Gains from Investment Securities: 2018-2025

Historic Gains from Investment Securities for Ensysce Biosciences (ENSC) over the last 5 years, with Jun 2025 value amounting to $102,785.

  • Ensysce Biosciences' Gains from Investment Securities fell 82.32% to $102,785 in Q2 2025 from the same period last year, while for Jun 2025 it was $102,785, marking a year-over-year decrease of 82.32%. This contributed to the annual value of $38,785 for FY2024, which is negligibly% changed negligibly from last year.
  • Latest data reveals that Ensysce Biosciences reported Gains from Investment Securities of $102,785 as of Q2 2025, which was up 13.22% from $90,785 recorded in Q1 2025.
  • Ensysce Biosciences' 5-year Gains from Investment Securities high stood at $6.7 million for Q2 2022, and its period low was $1,600 during Q1 2021.
  • Its 3-year average for Gains from Investment Securities is $234,808, with a median of $96,785 in 2025.
  • Its Gains from Investment Securities has fluctuated over the past 5 years, first plummeted by 92.65% in 2022, then surged by 2,109.14% in 2024.
  • Ensysce Biosciences' Gains from Investment Securities (Quarterly) stood at $4.4 million in 2021, then crashed by 92.65% to $58,435 in 2022, then plummeted by 91.95% to $26,314 in 2023, then surged by 2,109.14% to $581,314 in 2024, then crashed by 82.32% to $102,785 in 2025.
  • Its last three reported values are $102,785 in Q2 2025, $90,785 for Q1 2025, and $581,314 during Q3 2024.